SEC Form 4 · accession 0001209191-17-022050
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard A. Edlin
Director
Period of report
Mar 17, 2017
Accepted (ET)
Mar 21, 2017 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $81.27 | Mar 17, 2017 | A | 10,000 | A | — | Mar 16, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1One-third of the shares will vest annually over a three-year period such that the option is fully vested on the third anniversary of the date of grant, subject to the reporting person's continuous service with the issuer through each such vesting date.